XFOR · X4 Pharmaceuticals, Inc
$4.00
+0.07 (+1.78%)
At close · Jul 29
Market Cap
$370.68M
Shares
94.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.93
Open$3.95
Day$3.71–3.96
52W$1.35–4.83
Avg vol 30d946K
Short int6.5M · 6.9% float · 9.8d
Short vol29%
Last earningsMay 1, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−2%
trailing
YTD return
−2%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
7 of 82 funds reported for Jun 30 · net +33.1K sh shares · +3 new
Insider flow
Distributing
Net -$109.2K over 90 days · 100% sells
Short interest
Rising
6.89% of float · ▲ +18.1% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 1-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+150%
Y/Y
EPS growth
+67%
Y/Y
Free cash flow
$-85.9M
Balance sheet
$162.5M
net cash
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
7 of 82 funds reported for Jun 30 · net +33.1K sh shares · +3 new
Insider flow
Distributing
Net -$109.2K over 90 days · 100% sells
Short interest
Rising
6.89% of float · ▲ +18.1% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $4 · 74%
52-wk high $5
vs 200-day avg +2%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XFOR
this stock
X4 Pharmaceuticals, Inc
|
$370.68M | -1.8% | +150.0% | — | 6.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XFOR | +6.5% | -7.1% | -1.8% | -15.9% | -1.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +7.5% | -7.1% | -9.2% | -15.1% | -10.4% |